Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?

Published:2020-11 Issue: Volume:61 Page:103046
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Ray-Coquard Isabelle,Vanacker Hélène,Le Saux Olivia,Tredan Olivier

Funder

AstraZeneca France

Sandoz

Pfizer

Daiichi Sankyo Company

Novartis

British Microcirculation Society

Astellas Pharma

Meso Scale Diagnostics

Roche

GlaxoSmithKline Australia

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference10 articles.

1. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial;Pujade-Lauraine;Lancet Oncol,2017

2. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA Trial;Del Campo;J Clin Oncol,2019

3. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial;Coleman;Lancet,2017

4. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer;Moore;N Engl J Med,2018

5. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer;Ray-Coquard;N Engl J Med,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model;Molecular Cancer Therapeutics;2023-07-24

2. Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade;International Journal of Molecular Sciences;2023-06-30

3. Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer;Scientific Reports;2023-02-27

4. Study of Ferroptosis Transmission by Small Extracellular Vesicles in Epithelial Ovarian Cancer Cells;Antioxidants;2023-01-12

5. Evaluation of miR-141-3p over-expression in ovarian cancer;Electronic Journal of Biotechnology;2022-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3